Lewy Body Dementia in 2026: Diagnosis, Biomarkers, Treatment, and What Patients and Families Should Know

Cognitive & Movement Disorders
Anton Ostashko, MD·Last medically reviewed July 10, 2026

Overview

Lewy body dementia (LBD) is an umbrella term for two closely related clinical diagnoses caused primarily by abnormal accumulation of alpha-synuclein in the brain:

  • Dementia with Lewy bodies (DLB): dementia begins before, at the same time as, or within one year of parkinsonian movement symptoms.
  • Parkinson’s disease dementia (PDD): dementia develops after well-established Parkinson’s disease, traditionally more than one year after motor onset.12

The “one-year rule” is a clinical convention, not proof that these are biologically separate diseases. Both can affect attention, executive and visuospatial function, movement, sleep, mood, perception, blood pressure, bowel and bladder function, and medication tolerance.

The major 2024–2026 advance is the growing availability of alpha-synuclein biomarker tests. Cerebrospinal-fluid seed amplification assays and skin biopsy for phosphorylated alpha-synuclein can support the presence of a synucleinopathy. They do not replace the clinical diagnosis, do not by themselves distinguish DLB from Parkinson disease or multiple system atrophy, and can reveal mixed pathology rather than a single explanation for dementia.345

  • Diagnosis remains clinical. The pattern and timing of cognitive, visual, sleep, motor, and autonomic symptoms are central.
  • Biomarkers are supportive, not standalone verdicts. Assay method, disease stage, co-pathology, and pretest probability matter.
  • Cholinesterase inhibitors are the best-established symptomatic cognitive treatment. Rivastigmine is FDA-approved for Parkinson’s disease dementia, while use in DLB and use of donepezil in DLB are generally off-label in the United States.67
  • Antipsychotic sensitivity is a major safety issue. Dopamine-blocking drugs can produce profound worsening, rigidity, confusion, sedation, autonomic instability, or a life-threatening reaction in susceptible patients.18
  • No treatment has yet been proven to stop alpha-synuclein neurodegeneration. Neflamapimod and other disease-modifying strategies remain investigational.

Evidence cutoff: This article reflects publicly available evidence through July 10, 2026. Biomarker availability and laboratory validation vary. A positive alpha-synuclein test should be interpreted by a clinician familiar with synucleinopathies and mixed dementia.

The Core Clinical Pattern

1. Cognitive fluctuations

Attention and alertness can vary markedly over minutes, hours, or days. A person may stare, become unusually sleepy, speak less clearly, or seem confused and then return closer to baseline. Fluctuation is not specific to DLB: seizures, medications, sleep disorders, infection, metabolic illness, and delirium must be considered.

2. Recurrent visual hallucinations

Hallucinations are often detailed and well formed—people, children, or animals—and may occur early. Some patients retain insight; others become frightened or act on what they see. Illusions, passage hallucinations, a sensed presence, and misidentification syndromes can also occur.

3. REM sleep behavior disorder

Dream-enactment behavior—talking, shouting, punching, kicking, or falling from bed—can begin years before dementia or parkinsonism. Confirmation by polysomnography shows REM sleep without normal muscle atonia and is an indicative DLB biomarker under the consensus criteria.110

4. Parkinsonism

Bradykinesia, rigidity, gait change, reduced arm swing, soft speech, and tremor may occur. Tremor is not required. People with DLB may be more vulnerable than typical Parkinson disease patients to confusion, hallucinations, or low blood pressure when dopaminergic medication is increased.

Other common features

  • Early visuospatial difficulty, navigation problems, impaired attention, or executive dysfunction
  • Depression, anxiety, apathy, delusions, or misidentification
  • Orthostatic hypotension, constipation, urinary dysfunction, erectile dysfunction, or reduced sweating
  • Reduced smell, excessive daytime sleepiness, insomnia, and sleep apnea
  • Falls, fainting, sensitivity to heat, or unexplained episodes of reduced responsiveness
  • Speech and swallowing difficulty later in the course

Memory loss may be less prominent early than in typical Alzheimer’s disease, but mixed Alzheimer and Lewy body pathology is common. A patient may therefore have both an amnestic Alzheimer-type profile and core DLB features.

How DLB and PDD Are Diagnosed

The 2017 DLB criteria classify dementia plus core clinical features and indicative biomarkers. In practice, diagnosis begins with a detailed timeline from both the patient and a knowledgeable care partner.1

Clinical assessment

  • Cognitive and functional history, including attention, navigation, finances, medications, and driving
  • Neurological examination for parkinsonism, eye-movement abnormalities, gait, balance, and neuropathy
  • Medication review, especially anticholinergics, sedatives, dopamine blockers, bladder medications, and sleep aids
  • Orthostatic blood pressure and autonomic symptom review
  • Sleep history, including dream enactment and sleep apnea
  • Laboratory evaluation for reversible or contributing causes
  • Brain MRI or CT to look for stroke, tumor, hydrocephalus, vascular disease, and patterns of atrophy
  • Neuropsychological testing when detailed characterization will change diagnosis or care

Established indicative biomarkers

  • Reduced dopamine-transporter uptake in the basal ganglia on SPECT or PET supports a degenerative parkinsonian syndrome. It does not uniquely identify DLB and can be normal early.
  • Polysomnographic REM sleep without atonia supports REM sleep behavior disorder.
  • Reduced cardiac MIBG uptake is included in the consensus criteria but is used more routinely in some countries than in the United States and can be confounded by heart disease, diabetes, and medications.1

FDG-PET may show occipital hypometabolism and relative preservation of posterior cingulate metabolism—the “cingulate island sign.” Structural MRI often shows relative preservation of medial temporal structures compared with typical Alzheimer’s disease. These are supportive patterns, not definitive individual tests.

Alpha-Synuclein Biomarkers: The 2024–2026 Advance

Skin biopsy

In a 2024 cross-sectional study of 428 participants selected for clinically defined synucleinopathies or control status, cutaneous phosphorylated alpha-synuclein was detected in 96.0% of participants with DLB and in 3.3% of controls. Detection was also high in Parkinson disease, multiple system atrophy, and pure autonomic failure.3

Those impressive results do not mean the test is 96% accurate in every memory clinic. The study was not a general-population screening trial; participants were clinically characterized, biopsy technique and processing were standardized, and disease prevalence affects predictive value. A positive result supports a synucleinopathy, not specifically DLB.

CSF seed amplification assays

Seed amplification assays amplify the misfolding activity of alpha-synuclein “seeds” in cerebrospinal fluid. A 2026 multicenter laboratory comparison found strong diagnostic performance for DLB but also demonstrated that protocols and inter-laboratory characteristics matter.5

These tests may be especially helpful when the clinical picture is ambiguous or when mixed Alzheimer and Lewy body disease is suspected. Limitations include lumbar puncture, assay access, variability among platforms, reduced sensitivity in some focal or early pathologic distributions, and the inability of a simple positive/negative result to define the full clinical syndrome.4

What a positive test means: Pathologic alpha-synuclein has been detected by the assay used. It does not automatically explain every symptom, stage the disease, predict the rate of decline, or prove that Alzheimer, vascular, or other co-pathology is absent.

A Critical Safety Issue: Antipsychotic Sensitivity

People with DLB can experience severe worsening after antipsychotics, especially potent dopamine D2 blockers. Possible reactions include marked rigidity, immobility, sedation, confusion, swallowing difficulty, falls, autonomic instability, and neuroleptic malignant syndrome. Older studies documented substantial morbidity and mortality from neuroleptic sensitivity in Lewy body dementia.8

Before prescribing an antipsychotic, clinicians should:

  1. Look for infection, pain, constipation, urinary retention, dehydration, sleep loss, or medication toxicity.
  2. Decide whether the hallucination is distressing or dangerous. Benign hallucinations with retained insight may not require medication.
  3. Reduce anticholinergic and other aggravating medications when safe.
  4. Optimize a cholinesterase inhibitor when appropriate.
  5. Use the lowest-risk drug at the lowest effective dose only after individualized discussion of the boxed warning for increased mortality in older adults with dementia-related psychosis.

Pimavanserin is FDA-approved for hallucinations and delusions associated with Parkinson’s disease psychosis. It is not broadly approved for dementia-related psychosis unrelated to Parkinson disease, and it can prolong the QT interval.9 Quetiapine is frequently used off-label when medication is necessary; clozapine can be effective but requires blood monitoring. Evidence in DLB remains less robust than many families assume.

Treatment and Management

Cognition and fluctuations

Cholinesterase inhibitors can improve or stabilize cognition, attention, function, and sometimes hallucinations. Rivastigmine carries a U.S. indication for mild-to-moderate dementia associated with Parkinson’s disease, not specifically for DLB. Donepezil has randomized-trial evidence in DLB but is off-label for that diagnosis in the United States.67

Adverse effects include nausea, diarrhea, weight loss, vivid dreams, slowed heart rate, fainting, and urinary symptoms. Baseline pulse, cardiac history, weight, and drug interactions matter. Memantine is sometimes used, but trial results in Lewy body dementia are mixed.

Movement symptoms

Levodopa can improve bradykinesia and rigidity in some patients, but response may be less robust than in typical Parkinson disease and hallucinations or orthostatic hypotension can worsen. Treatment should target function rather than a normal-looking examination.

REM sleep behavior disorder

Start with bedroom safety: remove weapons and sharp objects, pad corners, lower the bed, consider separate sleeping arrangements during violent episodes, and treat coexisting sleep apnea. Immediate-release melatonin and clonazepam are commonly used conditionally; clonazepam may worsen falls, cognition, or sleep apnea, especially in older adults.10

Autonomic symptoms

  • Hydration, slow position changes, compression garments, and medication review for orthostatic hypotension
  • Individualized salt strategy when medically safe
  • Selected medications such as midodrine, droxidopa, or fludrocortisone when necessary
  • Bowel regimen and evaluation of urinary symptoms before adding anticholinergic drugs

Rehabilitation and daily safety

Physical therapy, occupational therapy, speech and swallowing therapy, exercise, fall prevention, vision optimization, hearing care, and home-safety modifications are central. Driving should be reassessed when fluctuations, visuospatial impairment, hallucinations, or slowed reactions emerge.

Medications That Commonly Create Problems

  • Typical antipsychotics and potent dopamine blockers
  • Metoclopramide and prochlorperazine, which can worsen parkinsonism
  • Strong anticholinergics, including many bladder and over-the-counter sleep medications
  • Benzodiazepines and sedatives that worsen confusion, falls, or breathing
  • Dopamine agonists and amantadine when hallucinations or impulse-control problems are prominent
  • Blood-pressure drugs that worsen symptomatic orthostatic hypotension

No medication should be stopped abruptly based on this list. The goal is a structured review of benefit, burden, and safer alternatives.

Research to Watch

Neflamapimod

Neflamapimod is an investigational oral p38α kinase inhibitor. The Phase 2b RewinD-LB program enrolled a biomarker-enriched DLB population and sponsor-reported analyses have supported continued development. The trial record should be interpreted alongside the eventual peer-reviewed publication and prespecified statistical plan.11

A separate 2026 study evaluated a higher dose for safety, tolerability, and pharmacokinetics and was listed as completed with no posted results as of the evidence cutoff.12 Neflamapimod is not FDA-approved and should not be described as proven disease-modifying therapy.

Biomarker-driven trials

Alpha-synuclein assays may improve trial enrollment by identifying participants with biological evidence of a synucleinopathy and by recognizing Alzheimer co-pathology. The crucial next step is to show that a therapy meaningfully preserves cognition, function, safety, or quality of life—not merely that a biomarker changes.

When to Seek Urgent Care

  • Sudden one-sided weakness, speech change, loss of vision, or severe new imbalance
  • New prolonged unresponsiveness, seizure, or rapidly worsening confusion
  • Fever, marked rigidity, autonomic instability, or reduced consciousness after an antipsychotic or dopamine-blocking drug
  • Repeated fainting, injury, inability to swallow, or aspiration
  • Suicidal thoughts, violent behavior, or inability to maintain safety at home

Acute confusion should not automatically be attributed to “fluctuation.” Delirium from infection, medication, dehydration, pain, or another medical illness is common and treatable.

A Practical Framework for Families

  1. Build the timeline. Establish when cognitive, motor, sleep, hallucination, and autonomic symptoms began.
  2. Look for mixed disease. Alzheimer and vascular pathology often coexist and may alter prognosis and treatment.
  3. Use biomarkers to answer a defined question. Do not order alpha-synuclein testing as an isolated screening result without clinical interpretation.
  4. Prioritize medication safety. Keep an updated list and make emergency clinicians aware of possible Lewy body dementia and antipsychotic sensitivity.
  5. Treat the whole syndrome. Cognition, movement, sleep, blood pressure, bowel and bladder function, mood, swallowing, falls, and caregiver burden all matter.

Bottom line: Lewy body dementia is a multisystem neurodegenerative syndrome in which early recognition changes care. New alpha-synuclein biomarkers can strengthen diagnostic confidence, but they do not replace the history or define prognosis by themselves. Treatment remains symptomatic and safety-centered while disease-modifying research continues.

At Los Altos Neurology, evaluation integrates cognitive and movement history, autonomic and sleep assessment, medication-safety review, neuropsychological testing, imaging, and selective biomarker use to build a practical plan for patients and care partners.

References

  1. McKeith IG, Boeve BF, Dickson DW, et al. Neurology. 2017;89:88-100. Fourth consensus report of the DLB Consortium.
  2. Emre M, Aarsland D, Brown R, et al. Mov Disord. 2007;22:1689-1707. Clinical diagnostic criteria for dementia associated with Parkinson disease.
  3. Gibbons CH, Levine T, Adler C, et al. JAMA. 2024;331:1298-1306. Skin biopsy detection of phosphorylated α-synuclein in synucleinopathies.
  4. Review of emerging α-synuclein biomarkers in clinical synucleinopathies. 2026. CSF α-synuclein seed amplification assays and skin phosphorylated α-synuclein testing.
  5. Kumar R, et al. Neurology. 2026;106:e214614. doi:10.1212/WNL.0000000000214614. Diagnostic performance of CSF α-synuclein seed amplification assay for DLB across laboratories.
  6. U.S. Food and Drug Administration. Rivastigmine transdermal system labeling. 2018. EXELON PATCH prescribing information.
  7. Ikeda M, Mori E, Matsuo K, et al. Alzheimers Res Ther. 2015;7:4. Donepezil for dementia with Lewy bodies: randomized Phase III trial.
  8. McKeith I, Fairbairn A, Perry R, et al. BMJ. 1992;305:673-678. Neuroleptic sensitivity in patients with senile dementia of Lewy body type.
  9. U.S. Food and Drug Administration. Pimavanserin labeling. 2026. NUPLAZID prescribing information.
  10. Howell M, Avidan AY, Foldvary-Schaefer N, et al. J Clin Sleep Med. 2023;19:759-768. AASM clinical practice guideline for REM sleep behavior disorder.
  11. ClinicalTrials.gov. NCT05869669. Neflamapimod in dementia with Lewy bodies. RewinD-LB Phase 2b trial record.
  12. ClinicalTrials.gov. NCT06815965. Completed; no results posted as of July 10, 2026. 2026 neflamapimod safety and pharmacokinetic study.

Medical disclaimer. This article is provided for general educational and informational purposes only. It does not constitute individualized medical advice, diagnosis, treatment, a recommendation for any specific test or therapy, or informed consent. Medical information changes over time, and this article may not reflect developments occurring after its stated review date or apply to your individual circumstances. Do not disregard or delay professional medical advice, or start, stop, or change any medication or treatment, based on this article. Discuss personal medical decisions with a qualified healthcare professional who can evaluate your individual history and circumstances. Accessing or using this website does not, by itself, create a physician–patient relationship with Los Altos Neurology or any of its clinicians. Do not use this website for urgent or emergency medical concerns; call 911 or seek immediate emergency care. Although Los Altos Neurology makes reasonable efforts to provide accurate and current information, it does not guarantee that all content is complete, current, or applicable to every individual. See our full Medical Disclaimer.